Who Owns Pepcid?

Pepcid operates under Kenvue's corporate sustainability framework. Kenvue has committed to reducing environmental impact across its operations and supply chain. The company's 2024 sustainability report outlined targets including carbon emission reductions, sustainable packaging improvements, and responsible sourcing.

Kenvue's manufacturing facilities implement environmental management systems including energy efficiency programs, waste reduction, and water conservation. Specific environmental data for Pepcid production is not separately disclosed, as Kenvue reports sustainability metrics at the corporate level.

Famotidine, Pepcid's active ingredient, has been detected in environmental water samples in some studies, raising concerns about pharmaceutical contamination of waterways. This is an industry-wide issue for pharmaceuticals, not specific to Pepcid. Kenvue and other manufacturers are required to comply with FDA environmental assessment requirements for pharmaceutical manufacturing.

Pepcid does not carry independent sustainability certifications, as such certifications are not standard for pharmaceutical products. The brand's environmental and social performance is governed by Kenvue's corporate policies and FDA regulatory requirements.

Kenvue has committed to making healthcare products accessible and affordable. The company offers patient assistance programs and participates in drug discount programs. However, as an OTC product, Pepcid is generally affordable and not a primary focus of access initiatives, which target prescription medications.

The most significant event in Pepcid's history was the 2009-2011 manufacturing quality crisis at Johnson and Johnson's McNeil Consumer Healthcare unit. In September 2009, McNeil initiated recalls of multiple products including Pepcid Complete due to manufacturing quality issues at its Fort Washington, Pennsylvania facility. The recalls expanded through 2010 and affected Tylenol, Motrin, Benadryl, and other J and J products.

The Fort Washington facility was closed by the FDA in April 2010 due to multiple manufacturing violations, including unsanitary conditions, quality control failures, and inadequate record-keeping. J and J invested approximately $100 million to upgrade the facility, which reopened in 2013. The manufacturing crisis resulted in Pepcid Complete being unavailable for approximately two years, creating confusion among consumers and healthcare providers.

The J and J manufacturing crisis led to multiple congressional hearings, FDA warning letters, and a consent decree with the FDA in 2011. The consent decree required J and J to implement comprehensive quality remediation at its McNeil facilities. The company paid approximately $25 million in penalties and compliance costs.

In 2020, famotidine received attention as a potential COVID-19 treatment after observational studies suggested possible benefits. This led to famotidine shortages in some markets as consumers stockpiled the medication. The FDA did not authorize famotidine for COVID-19 treatment, and subsequent randomized clinical trials did not confirm a benefit. Kenvue and generic manufacturers increased production to address the temporary shortage.

In 2024, the FDA announced a voluntary recall of one lot of generic famotidine tablets manufactured by Aurobindo Pharma due to the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen. This recall did not involve branded Pepcid products. The NDMA contamination issue has affected multiple pharmaceutical products in recent years, including valsartan, metformin, and ranitidine (Zantac). Ranitidine was withdrawn from the U.S. market in 2020 due to NDMA concerns, which benefited Pepcid as famotidine became the primary remaining H2 blocker on the market.